Journal of Chemotherapy最新文献

{"title":"Oritavancin as sequential therapy for vancomycin-resistant <i>Enterococcus faecium</i> prosthetic valve endocarditis: a case report.","authors":"Christina Petropoulou, George Eleftherakis, Alexandros Tousis, Theodore Bibis, Anastasios Nikas, Eugenia Drosou, Christos Davoulos, Stelios F Assimakopoulos","doi":"10.1080/1120009X.2026.2674359","DOIUrl":"10.1080/1120009X.2026.2674359","url":null,"abstract":"<p><p>We report the case of a 91-year-old man with prosthetic valve endocarditis (PVE) caused by vancomycin-resistant <i>Enterococcus faecium</i> (VRE), successfully managed with an initial two-week course of intravenous daptomycin and fosfomycin, followed by six once-weekly outpatient infusions of oritavancin. The diagnosis was established based on positive blood cultures and transoesophageal echocardiography findings. In the challenging epidemiological setting of Greek hospitals-characterized by endemic multidrug-resistant organisms and a high burden of healthcare-associated infections-minimizing hospitalization is a key consideration. Oral linezolid was avoided due to its bacteriostatic activity, relatively low serum levels, and the risk of myelotoxicity in elderly patients. The patient achieved complete clinical and microbiological resolution and remained relapse-free at six months of follow-up. This case highlights the feasibility of long-acting lipoglycopeptides, such as oritavancin, as sequential therapy to enable outpatient completion of prolonged treatment in selected patients with VRE prosthetic valve endocarditis.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.1,"publicationDate":"2026-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148005387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of low-volume hydration on kidney function in low-dose cisplatin therapy for biliary tract cancer: a multicentre retrospective cohort study.","authors":"Hiroyuki Watanabe, Katsuya Makihara, Masahiko Nakao, Mizuho Haruta, Masaya Takahashi, Hirotake Yamase, Mayuka Hosoda, Keisuke Kongo, Hideto Takatori, Atsushi Kondo, Hiroshi Yamamoto, Naotaka Kimura, Katsuyuki Takahashi","doi":"10.1080/1120009X.2026.2672254","DOIUrl":"10.1080/1120009X.2026.2672254","url":null,"abstract":"<p><p>Hydration is crucial for preventing cisplatin-induced nephrotoxicity; however, optimal hydration for low-dose cisplatin (<50 mg/m²) remains unclear. This multicentre retrospective study assessed whether low-volume hydration (LV, <1500 mL) is non-inferior to high-volume hydration (HV, ≥1500 mL) in patients with biliary tract cancer receiving gemcitabine plus cisplatin (25 mg/m²). Of 239 patients, 109 LV and 97 HV patients were analysed. Primary endpoint was acute kidney injury (AKI) incidence. Propensity score weighting was applied to adjust for confounders. Post-adjustment AKI incidence was 4.7% (LV) vs. 10.1% (HV), confirming non-inferiority (risk difference upper 95% CI: 0.002, margin <0.05). No significant differences were observed in serum creatinine or creatinine clearance trajectories. In conclusion, low-volume hydration was non-inferior to high-volume hydration for AKI risk in low-dose cisplatin therapy. These findings support tailoring hydration to reduce patient burden without compromising safety.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147972874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of peripheral edema in cancer patients receiving MET inhibitors: a systematic review and meta-analysis.","authors":"Li Jing, Wen Xiong, Lina An","doi":"10.1080/1120009X.2026.2659402","DOIUrl":"10.1080/1120009X.2026.2659402","url":null,"abstract":"<p><p>Although MET inhibitors are increasingly used in cancer treatment, the overall risk and key determinants of treatment-related peripheral edema remain insufficiently characterized. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) published until September 2025. Thirty-five RCTs involving 10,555 patients were included. Our results demonstrated that MET inhibitors were associated with a significantly increased risk of all-grade (RR 2.76, 95% CI 2.13-3.57; <i>p</i> < 0.00001; ARD, 14.1%; NND, 7) and high-grade peripheral edema (RR 2.67, 95% CI 1.74-4.09; <i>p</i> < 0.00001; ARD, 0.88%; NND, 113). Elevated risks were observed with tepotinib, savolitinib, amivantamab, and rilotumumab. Notably, monoclonal antibodies carried a higher edema risk than tyrosine kinase inhibitors, and combination therapy showed greater risk than monotherapy. The risk was also higher in lung cancer and in first-line settings. These findings provide comprehensive evidence for the risk profile of peripheral edema and support individualized monitoring in clinical practice.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-15"},"PeriodicalIF":2.1,"publicationDate":"2026-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147815620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exposure-response analyses of pemigatinib in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement.","authors":"Xiaohua Gong, Ayman Akil, Boris Grinshpun, Jose Francis, Richard Khusial, Xiang Liu, Huiling Zhen, Mark Lovern, Xuejun Chen","doi":"10.1080/1120009X.2025.2497641","DOIUrl":"10.1080/1120009X.2025.2497641","url":null,"abstract":"<p><p>Pemigatinib is a selective, potent, orally administered inhibitor of fibroblast growth factor receptor (FGFR)1-3 with antitumor activity in multiple solid tumors. Pemigatinib is used to treat adults with previously treated metastatic or surgically unresectable cholangiocarcinoma with <i>FGFR2</i> alterations, as well as adults with relapsed or refractory myeloid/lymphoid neoplasm (MLN) with an <i>FGFR1</i> rearrangement (MLN-<i>FGFR1</i>). Data from recent clinical studies were used to develop pemigatinib exposure-response models for patients with MLN-<i>FGFR1</i> and to evaluate the impact of pemigatinib exposure on efficacy and safety. The degree of pemigatinib exposure did not predict the level of efficacy in patients with MLN-<i>FGFR1</i> in this analysis. Pemigatinib exposure was a significant predictor of the frequency of clinically relevant treatment-emergent adverse events. The estimated probabilities of developing hyperphosphatemia, dry mouth, nail toxicity, alopecia, stomatitis, and diarrhea were higher with a continuous dosing schedule versus an intermittent dosing schedule.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"302-308"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liposome-assisted combination chemotherapy improves the anti-proliferation and anti-angiogenesis response of cisplatin in breast cancer; experimental and computational study.","authors":"Nasim Valinezhadi, Gholamreza Dehghan, Mohammad Yaghoubzad-Maleki, Maryam Mohammadi, Ali Akbar Alizadeh, Hamed Hamishehkar","doi":"10.1080/1120009X.2025.2484078","DOIUrl":"10.1080/1120009X.2025.2484078","url":null,"abstract":"<p><p><b>Abstract</b>Combination chemotherapy using liposomes offers a promising approach to overcome chemotherapy resistance and minimize side effects in breast cancer treatment. This study explores the synergistic effects of all-trans-retinoic acid (ATRA) and cinnamaldehyde (CA) combined with cisplatin (CPT) in MDA-MB-231 breast cancer cells. The liposomal formulation, CPT_ATRA_CA, significantly reduced cell proliferation to 25.9 ± 2.8% compared to controls and effectively inhibited angiogenesis. Additionally, it induced apoptosis, as demonstrated by flow cytometry, DAPI staining, and an elevated Bax/Bcl-2 gene expression ratio. Computational analysis via molecular docking and molecular dynamics simulation revealed that ATRA exhibited the highest binding affinity for angiogenin (ANG) with a binding energy of -106.072 kcal/mol. Experimental results, corroborated by computational data, highlight the potent anti-tumor effects of this drug trio. These findings suggest that liposomal delivery of ATRA, CA, and CPT could enhance therapeutic outcomes in breast cancer by targeting multiple pathways synergistically.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"236-253"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between trastuzumab treatment interruption and survival in HER2-positive metastatic breast cancer patients: a retrospective study.","authors":"Ludmila Andrade Alves Ferreira, Mário Jorge Sobreira da Silva, Patricia Ribeiro Portella de Araújo, Maely Peçanha Fávero Retto","doi":"10.1080/1120009X.2025.2485520","DOIUrl":"10.1080/1120009X.2025.2485520","url":null,"abstract":"<p><p>This retrospective study analyzed the effect of trastuzumab treatment interruption on overall survival (OS) and progression-free survival (PFS) within two years after diagnosis in women with HER2-positive metastatic breast cancer. Sociodemographic, clinicopathological, and therapeutic variables were collected from medical records of patients diagnosed between 2013 and 2017 at a comprehensive cancer care center in Brazil. Survival estimates were performed using the Kaplan-Meier method and the log-rank test. The Cox Regression model was used to estimate the risk of outcomes. The average OS was 20.2 months, and the PFS was 13.1 months. Interruption of trastuzumab treatment was associated with an increase in overall survival time compared with continued treatment (22.5 months; 95% CI: 21.8 - 23.3 vs. 17.7 months; 95% CI: 15.9 - 19.4; <i>P</i> = 0.001). The adjusted risk model revealed that continued trastuzumab therapy was independently associated with a 2.86-fold increased risk of mortality.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"271-280"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PqsR-specific quorum sensing inhibitors targeting <i>Pseudomonas aeruginosa</i>: current advances and future directions.","authors":"Mandsaurwala Aziz, Kafil Ahmed, Vinothkannan Ravichandran","doi":"10.1080/1120009X.2025.2510093","DOIUrl":"10.1080/1120009X.2025.2510093","url":null,"abstract":"<p><p>The emergence of multidrug-resistant (MDR) Pseudomonas aeruginosa is driven by diverse resistance mechanisms, including quorum sensing (QS) and biofilm formation. QS regulates virulence, antibiotic tolerance, efflux pumps, and biofilm development, enhancing the pathogen's adaptability. Among QS systems, the Pseudomonas quinolone signal regulator (PqsR) plays a central role in controlling virulence and biofilm-associated genes. This review critically examines the PqsR-regulated network and highlights the potential of PqsR inhibitors to reduce pathogenicity. Disrupting QS instead of targeting bacterial viability can enhance antibiotic efficacy, making this combinatorial approach a promising strategy to combat MDR <i>P. aeruginosa</i>.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"199-216"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial cumulative area under the blood concentration-time curve of vancomycin is associated with the incidence of acute kidney injury.","authors":"Yuta Ibe, Tomoyuki Ishigo, Satoshi Fujii, Masahide Fukudo","doi":"10.1080/1120009X.2025.2561968","DOIUrl":"10.1080/1120009X.2025.2561968","url":null,"abstract":"<p><p>We aimed to evaluate the relationship between the cumulative area under the concentration-time curve (AUC) for the first and second day of vancomycin (VCM) administration and acute kidney injury (AKI). The primary outcome was the cumulative incidence of AKI. Patients were divided into three groups based on the measured AUC_0-48 h at the first therapeutic drug monitoring (TDM) (800 to less than 1000 µg·h/mL, Low-AUC group; 1000 to less than 1200 µg·h/mL, Moderate-AUC group; ≥1200 µg·h/mL, High-AUC group). Among 180 enrolled patients, 29 (16.1%) developed AKI. In the multivariate Cox proportional hazard analysis, the Moderate- (hazard ratio [HR]: 5.7, 95% confidence interval [CI]: 2.24-14.44) and High- (HR: 11.0, 95% CI: 3.88-31.39) AUC groups were associated with a higher incidence of AKI compared to the Low-AUC group. The accumulation toxicity of VCM was observed, and the cumulative AUC_0-48 h was associated with the development of AKI.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"225-235"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145175617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NCAPG2 promotes the proliferation, metastasis and resistance to nab-paclitaxel in gastric adenocarcinoma cells.","authors":"Jia Xu, Xiaoyuan Liu, Zebo Huang, Ying Zhang, Xia Li, Dongyan Cai","doi":"10.1080/1120009X.2025.2498230","DOIUrl":"10.1080/1120009X.2025.2498230","url":null,"abstract":"<p><p>Gastric adenocarcinoma is one of the most common cancers in the world. The purpose of this study was to investigate the role of non-smooth muscle cell aggregation protein II complex G2 subunit (NCAPG2) in gastric cancer cells. Cell growth, proliferation, migration, invasion and albumin-bound paclitaxel resistance were detected by cell counting kit-8, flow cytometry, Transwell chamber and nude mouse xenograft model. Western blot was used to detect the expression of NCAPG2, STAT3 and NF-κB signaling pathways. The expression of NCAPG2 was significantly up-regulated in gastric adenocarcinoma cells. Knockdown of NCAPG2 inhibited cell proliferation, migration and invasion, and inhibited tumor growth. In addition, knockdown of NCAPG2 reduced the resistance of gastric adenocarcinoma cells to albumin-bound paclitaxel and down-regulated STAT3 and NF-κB signaling pathways. In summary, NCAPG2 plays an important role in the malignant progression of gastric adenocarcinoma and is involved in the resistance to albumin-bound paclitaxel.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"254-263"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of dihydropyrimidine dehydrogenase deficiency testing for the prevention of fluoropyrimidine toxicity: a real-world experience in a Southern Italy cancer center.","authors":"Gabriella Bianchino, Alessandra Perrone, Alessandro Sgambato, Italo Sarno, Filomena Nozza, Ludmila Carmen Omer, Massimo Ulivi, Antonio Traficante, Biagina Campisi, Sabino Russi, Giovanni Calice, Geppino Falco, Alfredo Tartarone","doi":"10.1080/1120009X.2025.2489837","DOIUrl":"10.1080/1120009X.2025.2489837","url":null,"abstract":"<p><p>Fluoropyrimidines (FPs) are antineoplastic agents used for the treatment of various solid tumors, especially gastrointestinal cancers. Patients with variations in dihydropyrimidine dehydrogenase gene (<i>DPYD</i>), which can determine the partial or complete deficiency of the dihydropyrimidine dehydrogenase enzyme (DPD), are at an increased risk of developing severe and potentially life-threatening toxicity. Worldwide the introduction of pharmacogenetic testing into clinical practice has been a slow process and in our center the analysis of the <i>DPYD</i> gene has been adopted since April 2020. We evaluated the clinical application of routine DPYD screening and its ability to prevent early-onset of fluoropyrimidine-related toxicity in patients treated at the Oncology Reference Center of Basilicata (IRCCS-CROB), a recognized cancer centre in Southern Italy. From April 2020 to November 2022, 300 patients (male 137; female 163) diagnosed with various types of cancer were subjected to <i>DPYD</i> genotyping, before starting treatment with FPs. In accordance with the current European Medicines Agency (EMA) and the Italian Association of Medical Oncology (AIOM) guidelines patients were tested for four <i>DPYD</i> variants that are associated with reduced DPD activity. FPs dose adjustments in <i>DPYD</i> variant carriers were made following the previously mentioned guidelines. Three hundred patients underwent <i>DPYD</i> testing and thirteen (4.3%) patients were found to be heterozygous variant carriers; ten out of thirteen patients received FP dose reduction as indicated by the guidelines, one out of thirteen patients received alternative treatment, two of the thirteen patients received no treatment at all. The main toxicities observed in patients who received a <i>DPYD</i> genotype-based dose reduction were anemia, neutropenia, nausea and mucositis but events were primarily grade 1 or 2. Our experience confirms the technical feasibility and the usefulness of <i>DPYD</i> genotyping to reduce the risk of severe FPs toxicities.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"264-270"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}